Advanced in Membranous Nephropathy

Seung H. Han

Seoul, KR 
Advanced in Membranous Nephropathy
Seoul, KR 
OverviewLocationsClinical Research

Overview

Seung Han practices in Seoul, Republic of Korea. Mr. Han is rated as an Advanced expert by MediFind in the treatment of Membranous Nephropathy. His top areas of expertise are Chronic Kidney Disease, IgA Nephropathy, Glomerulonephritis, Kidney Transplant, and Percutaneous Coronary Intervention (PCI).

His clinical research consists of co-authoring 293 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Membranous Nephropathy.

Gender
Male

Locations

Seoul, Republic of Korea
Other Locations
Pohang, Republic of Korea
Suwon, Republic of Korea
Hwasung, Republic of Korea
Chuncheon, Republic of Korea
Incheon, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy
A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Low Dose Steroid, Cyclosporin, Low Dose Steroid
Study Phase: Phase 3
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
View 2 Less Clinical Trials

293 Total Publications

Proteinuria Trajectories: A Step Forward or Parallel Track in IgA Nephropathy Prediction?
Proteinuria Trajectories: A Step Forward or Parallel Track in IgA Nephropathy Prediction?
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: June 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Han's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile